HEREDITARY ANGIOEDEMA (HAE)
Clinical trials for HEREDITARY ANGIOEDEMA (HAE) explained in plain language.
Never miss a new study
Get alerted when new HEREDITARY ANGIOEDEMA (HAE) trials appear
Sign up with your email to follow new studies for HEREDITARY ANGIOEDEMA (HAE), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Daily pill aims to stop dangerous swelling attacks
Disease control Recruiting nowThis study is testing a long-term, daily oral tablet called deucrictibant to see if it can safely prevent the sudden, severe swelling attacks caused by hereditary angioedema (HAE). It will involve about 170 adolescents and adults with HAE who will take the pill once a day for ove…
Matched conditions: HEREDITARY ANGIOEDEMA (HAE)
Phase: PHASE3 • Sponsor: Pharvaris Netherlands B.V. • Aim: Disease control
Last updated Apr 02, 2026 02:11 UTC
-
New drug trial aims to protect kids from rare swelling disorder
Disease control Recruiting nowThis study is testing a drug called donidalorsen in children aged 2 to 12 who have hereditary angioedema (HAE), a rare condition that causes sudden, severe swelling. The main goal is to see if the drug is safe and well-tolerated in children, and to measure how it works in their b…
Matched conditions: HEREDITARY ANGIOEDEMA (HAE)
Phase: PHASE3 • Sponsor: Ionis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Apr 02, 2026 02:11 UTC
-
New shot aims to stop rare, painful swelling attacks
Disease control Recruiting nowThis study is testing whether regular injections of an experimental drug called navenibart can safely prevent the sudden, painful swelling attacks caused by hereditary angioedema (HAE). About 145 adults and teens with HAE will receive either the drug or a placebo (dummy shot) for…
Matched conditions: HEREDITARY ANGIOEDEMA (HAE)
Phase: PHASE3 • Sponsor: Astria Therapeutics, Inc. • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
Kids get lifeline to keep rare swelling disease at bay
Disease control AVAILABLEThis program allows children aged 2 to 11 with hereditary angioedema (HAE) to continue receiving a preventive drug called garadacimab after they finish a previous clinical trial. It is for kids who did well on the drug, had few or no swelling attacks, and had no major side effect…
Matched conditions: HEREDITARY ANGIOEDEMA (HAE)
Sponsor: CSL Behring • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
Tracking Takhzyro's Real-World impact on kids with rare swelling disorder
Disease control Recruiting nowThis study aims to understand how well the preventive medication Takhzyro (lanadelumab) works for children with hereditary angioedema (HAE) in everyday life. It will look at the medical records of about 40 children, aged 2 to under 12, who are already taking Takhzyro to prevent s…
Matched conditions: HEREDITARY ANGIOEDEMA (HAE)
Sponsor: Takeda • Aim: Disease control
Last updated Mar 18, 2026 14:41 UTC